Login to Your Account



Corixa Drops Bexxar Dispute, Prepares For ODAC Panel

By Kim Coghill


Wednesday, December 4, 2002
Corixa Corp.'s stock headed upward Tuesday following news that the FDA accepted additional data as well as responses to concerns raised about the biologics license application for Bexxar, the company's lead cancer product, and thus Corixa dropped its dispute resolution with the FDA. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription